SCP Vitalife Partners
VC Fund
Wayne, United States
SCP Vitalife Partners is a VC fund in Wayne focused on Health Care and Medical. SCP Vitalife is a Life Sciences Fundformed by SCP Partners , a U.S.-based investment organization with over $900 million in venture funds under management, and Vitalife , an experienced venture firm investing primarily in Israeli medical technology companies. The SCP Vitalife team includes investment professionals with prior experiences as seniorexecutives, clinical practitioners and venture capitalists.Their focus is on early to mid-stage life science technologies and services, with a concentration on therapeutic medical devices.They will continue to follow the successful formula of their predecessor fund, Vitalife Life Sciences Fund, offering their portfolio companies hands-on strategic assistance in planning, operations and finance. From their investment experience they have developed extensive networks to access capital, recruit management and facilitate favorable strategic alliances.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries SCP Vitalife Partners invests in
Stages SCP Vitalife Partners invests in
Countries SCP Vitalife Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series C
- $10M–$25M
- Series D
- $1.2M–$43M
Investment Focus
Industry
- Health Care 8 (67%)
- Medical 6 (50%)
- Medical Device 6 (50%)
- Biotechnology 5 (42%)
- Robotics 2 (17%)
Stage
- Series C 3 (25%)
- Series D 3 (25%)
- Funding Round 3 (25%)
- Seed 1 (8%)
- Series A 1 (8%)
Country
- Israel 6 (50%)
- United States 4 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Abraham Ludomirski
Partner
|
Partner | Total investments: 0 | Find email | |
Adi Shaked
Associate
|
Associate | Total investments: 0 | Find email | |
Charles C. Freyer
General Councel
|
General Councel | Total investments: 0 | Find email | |
Dennis P. Ferry
Chief Financhial officer
|
Chief Financhial officer | Total investments: 0 | Find email | |
|
Edna Charlap
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ivenix
|
Ivenix is a medical technology company that develops a next-generation infusion management system. It is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals.The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company was founded in 2007 and is headquartered in Amesbury, Massachusetts. | $42M / Sep 01, 2015 | |
MST Medical Surgery Technologies
|
Medical Surgery Technologies (MST) was founded in 2005 by Ziv Tamir and Moti Sholev, entrepreneurs with extensive experience in medical devices. MST leads the field of surgical analytics with its core image analytics technology designed to empower and automate the surgical environment, with a focus on medical robotics and computer-assisted surgery(MRCAS). The company's core technology is a software-based image analytics information platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics. The platform is positioned to enable the operating room of the future through real-time image analytics, connectivity and automation, providing value-added functionality for surgeon, provider and patient. MST’s initial offering is AutoLap™, the only robotic image-guided laparoscope positioning system. Powered by MST’s image-analysis software, AutoLap™ interacts with the surgeon’s movements in the surgical cavity, guiding the robotic laparoscope positioner in real time, offering the surgeon full and natural control of the surgical procedure and an optimal field of view. | $12.5M / Series C / Jul 01, 2015 | |
Lifeward
|
Lifeward develops, manufactures, and markets a walking system for persons with lower limb disabilities Its products include ReWalk Rehabilitation System and ReWalk Personal System. ReWalk Rehabilitation System allows walking, standing, sitting, and the capacity to ascend or descend stairs in the rehab center environment. The ReWalk Personal Systemis designed for everyday use in a range of environments. It can be used at home, work, or other locations and it functions outdoors and on different surfaces or terrains. The ReWalk Personal System allows sitting, standing, and turning as well as offers the ability to climb and descend stairs.The company changes the quality of life for individuals with lower limb disability by developing robotic technologies. Rewalk Robotics was founded on 2001 and is based in Marlborough, Massachusetts. | $1.2M / Series D / Jun 17, 2013 | |
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $43M / Series D / Mar 05, 2013 | |
Regentis Biomaterials
|
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. DrorSeliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™,designed for the treatment of articular cartilage lesions, is currently in clinical trials. | $10M / Series C / May 14, 2012 | |
|
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $500K / Feb 21, 2012 | |
|
Avedro
|
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States. | $25M / Series C / Jul 07, 2011 | |
NovoGI
|
novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management.NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years.NiTi's proprietary technology represents abreakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices. | $18.5M / Series F / Aug 11, 2009 | |
Garnet Biotherapeutics
|
Garnet BioTherapeutics is a clinical stage, venture-backed cell therapy company focused on dermal-based regenerative therapy. | $10.4M / Series A / Feb 03, 2009 | |
|
Sightline Technologies
|
Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel. | $10M / Series D / Aug 25, 2005 | |
| See all 12 investments → | |||
Co-Investors
Aperture Venture Partners
2 deals together
Israel Healthcare Ventures
2 deals together
OurCrowd
2 deals together
Abingworth
1 deal together
Agate Medical Investments
1 deal together
Alice Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SCP Vitalife Partners invest in?
SCP Vitalife Partners invests primarily in Health Care, Medical and Medical Device startups, most often at Series C and Series D stage. Most of the 12 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is SCP Vitalife Partners's check size?
SCP Vitalife Partners typically joins rounds of $10M–$25M at Series C and $1.2M–$43M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds SCP Vitalife Partners participates in.
How do I contact SCP Vitalife Partners?
Public channels for SCP Vitalife Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at SCP Vitalife Partners?
The team at SCP Vitalife Partners includes Abraham Ludomirski (Partner), Adi Shaked (Associate) and Charles C. Freyer (General Councel), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
